Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
Day One Biopharmaceuticals was a Nasdaq-listed biopharmaceutical company focused on targeted therapies for people of all ages with life-threatening diseases. News about DAWN centered on oncology product and pipeline developments, including OJEMDA (tovorafenib), an FDA-approved medicine marketed in the U.S. for pediatric low-grade glioma, and clinical-stage assets in rare cancers.
Coverage also includes the completed acquisition by Servier, related shareholder-rights and governance notices, capital-structure updates, operating and financial results, and clinical or regulatory disclosures tied to OJEMDA and other oncology programs.
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company, has announced its participation in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 7 at 2:50 p.m. ET. A live audio webcast of the chat will be accessible on the company’s website, with a replay available for 30 days.
The company specializes in targeted therapies for life-threatening diseases, highlighting its lead product candidate, DAY101, which is currently in a pivotal Phase 2 trial for low-grade glioma in younger patients.
On January 5, 2022, Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 10:30 a.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for 30 days afterwards. Day One is focused on developing targeted therapies for life-threatening diseases, including its lead candidate DAY101, currently in a pivotal Phase 2 trial for pediatric low-grade glioma.
Day One Biopharmaceuticals (Nasdaq: DAWN) has commenced dosing the first patient in a Phase 2 clinical trial evaluating DAY101 as a monotherapy for patients with RAF-altered solid tumors. DAY101 is a pan-RAF kinase inhibitor targeting the MAPK pathway. The multi-center study, FIRELIGHT-1, aims to assess the safety and efficacy of DAY101 with an overall response rate as the primary endpoint. Day One plans to initiate a Phase 1b combination study with its MEK inhibitor, pimasertib, in Q1 2022, while continuing to gather data from a pivotal trial in pediatric low-grade glioma patients.
Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will engage in a pre-recorded discussion, available on November 22 at 10:00 a.m. ET. This talk highlights Day One's mission to develop targeted cancer therapies, particularly for pediatric patients. The company’s lead product candidate, DAY101, is currently in a pivotal clinical trial for low-grade glioma. Access the webcasts via the Company's website.
Day One Biopharmaceuticals (Nasdaq: DAWN) reported significant progress in their pivotal Phase 2 FIREFLY-1 trial for DAY101, targeting pediatric low-grade glioma (pLGG). In Q3 2021, they secured Rare Pediatric Disease Designation and strengthened their leadership team. Financial highlights include cash reserves of $297.2 million, allowing operations to continue into H2 2023. R&D and G&A expenses surged to $9.8 million and $9.4 million, respectively, resulting in a net loss of $19.2 million for Q3 2021. Initial clinical data is anticipated in H1 2022.
Day One Biopharmaceuticals (Nasdaq: DAWN) reported a complete response in a pediatric patient with recurrent spindle cell sarcoma treated with DAY101 monotherapy, demonstrating its potential efficacy. This case will be presented at the 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting from November 10-13, 2021. DAY101, a type II pan-RAF inhibitor, targets key enzymes in the MAPK pathway and has shown good tolerability and encouraging activity in over 250 patients. The FDA has granted Breakthrough Therapy and Rare Pediatric Disease Designation for DAY101.
Day One Biopharmaceuticals (NASDAQ: DAWN) appointed Jaa Roberson as chief people officer to oversee human resources and talent acquisition. Roberson, with 20 years of HR experience in biopharma and health insurance, aims to contribute to the company's growth in targeted cancer therapies. CEO Jeremy Bender expressed confidence in her leadership, aligning with Day One’s mission to address critical unmet needs in cancer drug development, particularly for children. The firm is currently evaluating DAY101 in a pivotal Phase 2 clinical trial for low-grade glioma.
Day One Biopharmaceuticals (Nasdaq: DAWN) has appointed Scott Garland to its board of directors, enhancing its leadership team as it advances its pivotal Phase 2 FIREFLY-1 clinical trial of DAY101 in pediatric patients with progressive low-grade glioma. Garland brings over 30 years of biopharmaceutical experience, having successfully launched multiple therapies. DAY101, an investigational pan-RAF kinase inhibitor, has shown promising results in early trials, including good tolerability and anti-tumor activity. It is designed to target certain cancers, particularly in children.
Day One Biopharmaceuticals (Nasdaq: DAWN) reported significant advancements in the second quarter of 2021. The FDA has granted Rare Pediatric Disease Designation and the European Commission has awarded Orphan Designation for DAY101, aimed at treating low-grade gliomas. The company successfully dosed the first patients in the pivotal FIREFLY-1 trial. Furthermore, Day One raised $184 million in its initial public offering, ensuring funding into the second half of 2023. As of June 30, 2021, cash and equivalents stood at $310 million, supporting their ambitious clinical pipeline.
Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will participate in a panel discussion titled “Bullseye – Targeted Oncology Part 2” at the 12th Annual Wedbush PacGrow Healthcare Conference, scheduled for August 10-11, 2021. Dr. Bender's presentation is set for August 11 at 10:20 a.m. ET. The event will be held virtually, with webcasts available for live and archived viewing on the company's website. Day One is focused on developing targeted therapies for genomically defined cancers, especially for children.